Ziekenhuis Amstelland
- Address
- lock Available on a paid plan
Cardiovascular Diseases at Ziekenhuis Amstelland
Research at this hospital in Cardiology focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease, atrial fibrillation, and broader outcomes linked to heart and vascular risk. The trials are designed to test new treatment strategies, improve prevention, and evaluate whether therapies can reduce major events such as heart attack, stroke, and cardiovascular death.
- ASCVD prevention and reduction of major cardiovascular events
- Atrial fibrillation and stroke prevention after acute stress-related episodes
- Cardiovascular risk reduction in people with type 2 diabetes or overweight
Several studies also examine whether newer medicines can improve long-term heart and vascular outcomes when added to standard care.
Neoplasms and Cancer Treatment Research
The site is active in oncology research across several neoplasms, including breast cancer, metastatic colorectal cancer, and diffuse large B-cell lymphoma. These trials aim to refine treatment choices, explore treatment de-escalation where appropriate, and assess whether targeted or immune-based approaches can improve outcomes for people with difficult-to-treat cancers.
- Breast cancer, including triple negative breast cancer and HR-positive, HER2-negative disease
- Metastatic colorectal cancer and treatment intensity optimization
- Diffuse large B-cell lymphoma and prevention of treatment-related heart problems
This research combines efforts to improve cancer control while also considering safety, quality of life, and the balance between treatment benefit and burden.
Female Urogenital Diseases and Pregnancy Complications
Clinical studies in this area include research on infertility and reproductive health, with the goal of improving diagnostic and treatment pathways for women trying to conceive. The work also reflects interest in practical interventions that may support better fertility-related care in everyday clinical settings.
- Infertility and evaluation of fertility-related procedures
- Research aimed at improving the chances of conception leading to live birth
- Comparing approaches that may help guide reproductive care more effectively
At Ziekenhuis Amstelland, this field adds a reproductive health dimension to a portfolio that is otherwise strongly centered on cardiovascular and cancer research.
Hemic and Lymphatic Diseases
The hematology research portfolio includes studies in multiple myeloma and diffuse large B-cell lymphoma. These trials are focused on improving disease control, exploring treatment sequencing, and reducing complications from therapy, especially when patients need effective treatment over a longer period.
- Multiple myeloma and strategies for treatment-free intervals
- DLBCL and prevention of heart damage linked to cancer therapy
- Evaluating whether treatment approaches can preserve effectiveness while limiting toxicity
This area shows a clear interest in balancing cancer treatment benefit with safety, particularly in patients who may already face elevated cardiovascular risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1BOOG Study Center B.V.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ziekenhuis Amstelland
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 2 | Unknown | 2022-11-24 | 2024-01-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
